Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries

Circulation

Volumn 99, Issue 15, 1999, Pages 2003-2010

  Napoli, Claudio ^a   Witztum, Joseph L ^a   De Nigris, Filomena ^b   Palumbo, Giuseppe ^b   D'Armiento, Francesco P ^b   Palinski, Wulf ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b San Diego ^*

Author keywords

Atherosclerosis; Brain; Free radicals; Hypercholesterolemia; Lipoproteins; Stroke

Indexed keywords

APOLIPOPROTEIN B; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; LOW DENSITY LIPOPROTEIN; MANGANESE SUPEROXIDE DISMUTASE;

ARTICLE; ATHEROSCLEROSIS; BRAIN ARTERY; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; STROKE;

EID: 0033586684     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.2003     Document Type: Article

References (42)

1. Consensus Conference. Lowering blood cholesterol to prevent coronary heart disease. JAMA. 1985;253:2080-2090.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
4. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME. Reduction in coronary events during treatment with pravastatin: PLAC I and PLAC II Investigators: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Am J Cardiol. 1995;76:60C-63C.
5. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
7. Grundy SM. Primary prevention of coronary heart disease: role of cholesterol control in the United States. J Intern Med. 1997;241:295-306.
8. Postiglione A, Napoli C. Hyperlipidemia and atherosclerotic cerebrovascular disease. Curr Opin Lipidol. 1995;6:236-242.
9. Mathur KS, Kashyap SK, Kumar V. Correlation of the extent and severity of atherosclerosis in the coronary and cerebral arteries. Circulation. 1963;27:929-934.
10. McGill HC, Arias-Stella J, Carbonell LM, Correa P, DeVeyra EA, Donoso S, Eggen DA, Galindo L, Guxman MA, Lichtenberger E, Loken C, McGarry PA, McMahan CA, Montenegro MR, Moossy J, Perez-Tamayo R, Restrepo C, Robertson WB, Salas J, Solberg LA, Strong JP, Tejada C, Wainwright J. General findings of the International Atherosclerosis Project. Lab Invest. 1968;18:498-512.
11. Wissler RW, Vesselinovitch D. Atherosclerosis in nonhuman primates. Adv Vet Sci Comp Med. 1977;21:351-420.
12. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
13. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28: 946-950.
14. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119:136-145.
15. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of LDL and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
16. Pathobiological Determinants of Atherosclerosis in Youths (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study. Arterioscler Thromb. 1993;13:1291-1298.
17. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
18. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
19. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
20. Alaupovic P, Lee DM, McConathy WJ. Studies on the composition and structure of plasma lipoproteins: distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta. 1972;260:689-707.
21. Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism. 1990;39:269-273.
22. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler S, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
23. Gown AM, Tsukada T, Ross R. Human atherosclerosis: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
24. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun. 1976;71:952-958.
25. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126.
26. Marklund SL. Pyrogallol autoxidation. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton, Fla: CRC Press. Inc; 1985:243-255.
27. Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with Folin-Phenol reagent. J Biol Chem. 1951;193:265-275.
28. Weber G, Biancardi G, Cneit L, Resi L, Salvi M, Tanganelli P. Delayed cerebral atherosclerosis involvement in WHHL rabbits. In: Crepaldi G, Gotto AM Jr, Manzato E, Baggio G, eds. Atherosclerosis VIII. Heidelberg, Germany: Springer Verlag; 1989:125-128.
29. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85:391-40.5.
30. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478.
31. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate, II: fatty streak conversion to fibrous plaque. Arteriosclerosis. 1984;4:341-356.
32. Neary RH, Kilby MD, Kumpatula P, Game FL, Bhatnagar D, Durrington PN, O'Brien PMS. Fetal and maternal lipoprotein metabolism in human pregnancy. Clin Sci. 1995;88:311-318.
33. Turley SD, Burns DK, Rosenfeld CR, Dietschy JM. Brain does not utilize low density lipoprotein-cholesterol during fetal and neonatal development in the sheep. J Lipid Res. 1996;37:1953-1961.
34. Reese T, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34:207-217.
35. Connolly ES Jr, Huang J, Goldman JE, Holtzman RN. Immunohistochemical detection of intracranial vasa vasorum: a human autopsy study. Neurosurgery. 1996;38:789-793.
36. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apoE-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
37. Palinski W, Hörkkö S. Biological consequences of oxidation in atherosclerosis and other pathologies: lipoprotein oxidation in brain arteries. Nutr Metab Cardiovasc Dis. 1997;7:237-247.
38. 2, and ADP. Circulation. 1989;79:698-705.
39. Napoli C, Paternò R, Faraci FM, Taguchi H, Postiglione A, Heistad DD. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery. Stroke. 1997;28:2266-2272.
40. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93:10417-10422.
41. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
42. Libby P, Galis ZS. Cytokines regulate genes involved in atherogenesis. Ann N Y Acad Sci. 1995;748:158-168.